Table 2 Continuous 24-h ECG monitoring and functional tests before the procedure.
From: Effect of age on clinical impact and mid-term denervation in patients undergoing cardioneuroablation
< 50 years (n = 17) | ≥ 50 years (n = 33) | p-value | |
|---|---|---|---|
Minimum HR (bpm) | 41.3 ± 9.4 | 41.6 ± 9.5 | 0.942 |
Median HR (bpm) | 73.6 ± 19.7 | 69.6 ± 11.8 | 0.428 |
Maximum HR (bpm) | 124.2 ± 24.6 | 112.1 ± 21.4 | 0.127 |
SDNN 24 h (ms) | 165.5 ± 64.6 | 146.0 ± 35.6 | 0.225 |
RMSSD (ms) | 43 (28–72) | 26.5 (21.3–37) | 0.03 |
PNN50 (%) | 12 (8–32) | 5 (3–15) | 0.051 |
VLF (ms2) | 3553 (2509–4900) | 1925 (1236–2783) | 0.023 |
LF (ms2) | 1139 (1032–1308) | 469 (358–1039) | 0.011 |
HF (ms2) | 333 (272–599) | 116 (93–211) | 0.005 |
Relative HR variation with the Valsalva test (%) | 53.7 (31.7–72.6) | 24.4(12.9–34.1) | 0.016 |
Relative HR variation with the deep inspiration test (%) | 31.5 ± 15.2 | 23.0 ± 25.3 | 0.291 |
Relative HR variation with the atropine test (%) | 60.0 (42.9–90) | 62.6 (48.3–75.6) | 0.944 |
Maximum HR with the atropine test (bpm) | 117.9 ± 20.3 | 102.4 ± 22.0 | 0.037 |
